Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
- Authors
- Ahn, Jae-Sook; Kim, Yeo-Kyeoung; Min, Yoo Hong; Cheong, June-Won; Jang, Jun Ho; Jung, Chul Won; Kim, In Ho; Yoon, Hwi-Joong; Lee, Hong Ghi; Sohn, Sang Kyun; Moon, Joon Ho; Kim, Hawk; Kim, Yoo-Jin; Won, Jong-Ho; Chung, Joo-Seop; Mun, Yeung Chul; Lee, Je-Hwan; Kim, Hyeoung-Joon
- Issue Date
- 2015
- Publisher
- S. Karger AG
- Keywords
- Myelodysplastic syndrome; Azacitidine; Allogeneic stem cell transplantation
- Citation
- Acta Haematologica, v.134, no.1, pp 40 - 48
- Pages
- 9
- Journal Title
- Acta Haematologica
- Volume
- 134
- Number
- 1
- Start Page
- 40
- End Page
- 48
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18657
- DOI
- 10.1159/000368711
- ISSN
- 0001-5792
1421-9662
- Abstract
- Azacitidine (AZA) is commonly used in patients with myelo-dysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twentyone patients who were scheduled for their third to sixth cycle of AZA pre-treatment followed by allo-SCT were enrolled. AZA pre-treatment was interrupted early in 3 patients (14.3%) because of leukaemic transformation or death. The overall response rate to AZA pre-treatment was 57.1%. There were 2 cases of complete remission, 1 case of partial remission, and 9 cases of haematologic improvement. Fourteen patients (66.7%) received the planned allo-SCT and 5 patients were alive at the last follow-up. Three-year progression-free survival (PFS) and 3-year overall survival (OS) in the 14 patients who received allo-SCT were 30.0% (95% CI 3.3-56.7) and 42.9% (95% CI 17.1-68.7), respectively. PFS and OS were not influenced by response to AZA pre-treatment (p > 0.05). In this study, AZA had a role as a bridge therapy to prevent leukaemic transformation prior to selection of a donor for allo-SCT and showed low toxicity. It may be considered in patients with higher-risk MDS. (C) 2015 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18657)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.